Home | Register | Login | Inquiries | Alerts | Sitemap |  


Advanced Search
JKM > Volume 38(3); 2017 > Article
Kwon, Lee, and Cho: Conventional Western Medicine and Complementary and Alternative Medicine on Leg Cramps: A Literature Review

Abstract

Objectives

The objective of this review is to investigate the use of conventional Western medicine (WM) and complementary and alternative medicine (CAM) on leg cramps. Leg cramps are the occurrence of muscular spasm in the leg muscles which occur frequently in the elderly and are frequently observed in the clinical field.

Methods

Relevant clinical studies were searched from five medical databases including PubMed, KISS, RISS, OASIS, and J-STAGE. Systematic review, clinical studies, and clinical practice guideline were included in this review.

Results

In total, 27 clinical studies, 9 systematic review and meta-analysis, and 1 clinical practice guideline met the inclusion criteria. Included studies were classified and analyzed according to the type of intervention. Studies on quinine and magnesium have been most studied in WM and CAM, respectively. Although quinine shows some clinical effects on leg cramps, however, the risk of side effects are suggested. In addition, magnesium failed to improve the clinically significant effects in most studies. Five case reports using Oriental herbal medicine (OHM) were included and OHMs were effective in improving leg cramps without side effects, however, the quality of evidence was low. Clinical studies on other interventions were lacking.

Conclusions

The results of this study indicate that there is no definite treatment standard for leg cramps until now, and there are limitations such as low level of evidence and side effects for each treatment. OHM can be an effective alternative to conventional intervention on leg cramps, therefore, related clinical studies are needed.

Fig. 1
PRISMA flow diagram of studies included in this review
jkm-38-3-13f1.gif
Table 1
Clinical Studies on Leg Cramps
Study Design Population Intervention Duration Results
Pharmacological intervention in WM
(1) Quinine
Jones, 198314) Double-blind RCT, Cross-over design Nocturnal leg cramp, elderly, n=9 TG: Quinine sulphate 300mg/day
CG: Placebo
2 weeks for each intervention 2 weeks for washout Number of cramps: +
Severity of cramps: +
Duration of cramps: −
Sleep disturbance: −
No adverse event was reported.
Lim, 198615) Double-blind RCT, Parallel design Nocturnal leg cramp, n=25 TG: Quinine sulphate 300mg/day
CG: Placebo
2 weeks for each intervention Number of cramps: −
Severity of cramps: −
No adverse event was reported.
Warburton, 198716) Double-blind RCT, Cross-over design Nocturnal leg cramp, elderly, n=22 TG: Quinine bisulphate 300mg/day
CG: Placebo
3 weeks for each intervention
3 weeks for washout
Number of cramps: −
Severity of cramps: −
No adverse event was reported.
Note. They reported that they found a significant relationship between serum quinine concentration and attenuation of cramps.
Fung, 198917) Double-blind RCT, Cross-over design Nocturnal leg cramp, elderly, n=9 TG: Quinine sulphate 200mg/day
CG: Placebo
4 weeks for each intervention
1 week for washout
Number of cramps: +
Duration of cramps: +
Severity of cramps: +
2 participants who received quinine reported side effects; ‘tinnitus’ and ‘blurred vision’, respectively.
Connolly, 199218) Double-blind RCT, Cross-over design Nocturnal leg cramp, male, n=30 TG: Quinine sulphate 500mg/day
CG1: Vitamin E 800U/day
CG2: Placebo
4 weeks for each intervention
4 weeks for washout
Number of cramps: +
Severity of cramps: −
Sleep disturbance: +
1 participant who received quinine reported side effect; ‘pruritus with bruising’.
Note. Vitamin E was not effective in reducing leg cramp frequency, severity, or sleep disturbance.
Dunn, 199319) Double-blind RCT, Cross-over design Patients receiving quinine regularly, n=28 TG: Quinine sulphate 300mg/day
CG: Placebo
30 days for each intervention
3 days for washout
Number of cramps: +
No adverse event was reported.
Note. They reported that quinine is more effective for night cramps at a higher dose, but this runs the risk of more side effects.
Sidorov, 199320) Double-blind RCT, Cross-over design Nocturnal leg cramp, male, n=19 TG: Quinine bisulphate 200mg/day
CG: Placebo
3 weeks for each intervention
No washout period but 2 weeks for run-in period
Number of cramps: −
Intensity of cramps: −
Duration of cramps: −
2 participants who received quinine reported side effects; ‘dizziness’ and ‘nausea, myalgia, leukopenia and thrombocytopenia’, respectively.
Diener, 200221) Double-blind RCT, Parallel design Nocturnal leg cramp, n=94 TG: Quinine sulphate 400mg/day
CG: Placebo
2 weeks for each intervention Number of cramps: +
Intensity of cramps: +
Intensity of pain: +
Global efficacy(by physician): +
Global efficacy(by patient): −
6 participants who received quinine reported side effect; ‘tinnitus’, ‘vomiting’, ‘diarrhea’, ‘epicondylitis’, ‘allergic exanthem’ and ‘bronchitis’, respectively.
Note. They reported that only the observed tinnitus was interpreted as being related with quinine.
Woodfield, 200522) Double-blind RCT, N-of-1 design Leg cramp, elderly, n=10 TG: Quinine sulphate 200~300mg/day
CG: Placebo
2 weeks for each intervention
2 weeks for washout
Number of cramps: ±
Days of cramps: ±
No adverse event was reported.
Note. Number and days of cramps were significantly reduced in 3 participants, but not in the other 7 participants.
Jansen, 199423) Double-blind RCT, Parallel design Leg cramp, n=20 TG: Hydroquinine hydrobromide 300mg/day
CG: Placebo
2 weeks for each intervention Number of cramps: +
Severity of cramps: −
Duration of cramps: −
4 participants who received quinine reported side effect; 3 for ‘bitter taste’, and 1 for ‘mild obstipation’.
Note. All women participants were assigned to hydroquinine group while all men participants were assigned to placebo group, randomly.
Jansen, 199724) Double-blind RCT, Parallel design Leg cramp, n=106 TG: Hydroquinine hydrobromide 300mg/day
CG: Placebo
2 weeks for each intervention Number of cramps: +
Severity of cramps: −
Duration of cramps: −
11 participants who received quinine reported side effect; 10 for ‘bitter taste or dry mouth’, and 1 for ‘tinnitus’.
Note. They reported that hydroquinine-group participants who reported side-effects were slightly heavier than those who did not, and also had a higher body-mass index.
(2) Verapamil
Baltodano, 198825) Single-arm study, Open-label trial Treatment resistant nocturnal leg cramp who were taking quinine sulfate 260mg daily, elderly, n=8 Verapamil hydrochloride 120mg/day 8 weeks Seven of eight patients had improvement.
No adverse event was reported.
(3) Naftidrofuryl
Young, 199326) Double-blind RCT, Cross-over design Nocturnal leg cramp, n=14 TG: Naftidrofuryl oxalate 600mg/day
CG: Placebo
4 weeks for each intervention
2 weeks for washout
Number of cramps: −
5 participants who received quinine reported side effect; ‘mild gastrointestinal upset’.
Note. They reported that naftidrofuryl is an effective alternative to quinine in the treatment of this painful condition.
Non-pharmacological intervention in WM
(1) Injection on trigger point
Prateepavanich, 199927) Single-blind RCT, Parallel design Nocturnal leg cramp, n=24 TG: Xylocaine injection at the gastrocnemius
CG: Quinine sulfate 300mg/day
4 weeks for each intervention Number of cramps: +
Duration of cramps: +
Intensity of pain: +
Cramp index: +
Pain threshold of the gastocnemius TrPs: +
No adverse event was reported.
Note. They reported that the benefit of both strategies lasted up to four weeks following cessation of the treatment but the outcome of all measures (except pain threshold) were found to be significantly better in the group treated with TrP injection.
Kim, 201528) Single-arm study Nocturnal leg cramp, n=12 1~2mL of 0.25% lidocaine into each of the TrPs on the gastrocnemius muscles 4 weeks Number of cramps: +
Pain threshold of the gastrocnemius TrPs: +
Sleep disturbance: +
No adverse event was reported.
Diet and dietary supplement in CAM
(1) Magnesium
Frusso, 199931) Double-blind RCT, Cross-over design Nocturnal leg cramp, n=93 TG: Magnesium citrate 1800mg/day
CG: Placebo
4 weeks for each intervention
4 weeks for washout
Number of cramps: −
Severity of cramps: −
Duration of cramps: −
Sleep disturbance: −
Note. They reported that no differences in the percentage of common side effects(diarrhea, nausea, vomiting) between magnesium(10.7%) and placebo(10.1%) were.
Roffe, 200232) Double-blind RCT, Cross-over design Chronic nocturnal leg cramp, n=73 TG: Magnesium citrate 300mg/day
CG: Placebo
4 weeks for each intervention
2 weeks for washout
Number of cramps: −
Severity of cramps: −
Duration of cramps: −
Global efficacy(by patient): +
22 participants who received quinine reported side effect; 14 for ‘diarrhea’, 6 for ‘constipation’, and 2 for ‘nausea, indigestion or flatulence’.
Garrison, 201133) Double-blind RCT, Parallel design Nocturnal leg cramp, n=46 TG: 4 hour intravenous infusions of 250ml D5W with 20mmol of magnesium sulfate
CG: 4 hour intravenous infusions of 250ml D5W
5 days for each intervention Number of cramps: −
No adverse event was reported.
(2) Caffeine
Molema, 200734) Double-blind, Single-case study Nocturnal leg cramp, n=1 2 capsules containing 500 mg paracetamol 3 times a day during 1 week; 2 capsules containing 500 mg paracetamol/50 mg caffeine 3 times a day during the other week. Note. Number of cramps increased according to rise of serum caffeine concentration. They reported that caffeine can increase susceptibility to muscle cramps in humans.
Exercise and physical therapy in CAM
(1) Stretching exercise
Coppin, 200535) RCT, Parallel design Nocturnal leg cramp who were taking quinine sulfate routinely, elderly, n=111 TG: Stretching exercise
CG: No stretching exercise
12 weeks Number of cramps: −
Symptom burden: −
Severity of cramps: −
No adverse event was reported.
Hallegraeff, 201236) Single-blind RCT, Parallel design Nocturnal leg cramp, older adults, n=55 TG: Stretching exercise
CG: No stretching exercise
6 weeks Number of cramps: +
Severity of cramps: +
No adverse event was reported.
Note. The stretching exercise was consisted of calf stretching in standing, hamstring stretch in standing, and hamstring and calf stretch in sitting.
(2) Physical therapy
Choi, 201037) Case reports Nocturnal leg cramp, n=2 Muscle energy technique 1 time The numbers of cramps during 1 week were reduced in the 2 patients.
No adverse event was reported.
Note. The muscle energy technique was a manipulation on articulation sacroiliaca.
(3) Oriental herbal medicine
Tahara, 201138) Case reports Treatment resistant leg cramp who were taking Jakyakgamcho-tang, n=1 Sokyungwhalhyul-tang 2 months The number of cramps was reduced.
No adverse event was reported.
Ishida, 201439) Case reports Nocturnal leg cramp, n=5 Uchashinki-hwan 8~18 weeks The cramps disappeared in 3 patients, but no improvement was observed in the other patients.
No adverse event was reported.
Ito, 201540) Case reports Chronic leg cramp, n=7 Samul-tang 14~609 days Seven cases showed improvement of the symptoms, but 3 cases showed no improvement.
No adverse event was reported.
Kimura, 201541) Case reports Leg cramp, n=2 Jinmu-tang 4 weeks~6 months The number and severity of cramps were reduced in the 2 patients.
No adverse event was reported.
Dokura, 201742) Case reports Leg cramp, n=33 Sokyungwhalhyul-tang 1 month In 96.95% (32 cases), symptoms of the cramps were improved by more than half, and 69.6% (23 cases) reported that the symptoms disappeared.
No adverse event was reported.
Note. In particular, 36.4% (12 cases) showed no occurrence of the cramps immediately after taking Sokyungwhalhyul-tang.

Abbreviation: CAM, complementary and alternative medicine; CG, control group; RCT, randomized controlled trial; TG, treatment group; TrPs, trigger points; WM, conventional Western medicine. Note. ‘+’ means that the intervention used for treatment group showed significant clinical effects; ‘−’ means that the intervention used for treatment group had no significant effect; ‘±’ means that the intervention used for treatment group had conflicting effects according to participants.

참고문헌

1. Butler JV, Mulkerrin EC, O’Keeffe ST. Nocturnal leg cramps in older people. Postgrad Med J. 2002; 78:924. 596–8.
crossref

2. Hallegraeff J, de Greef M, Krijnen W, van der Schans C. Criteria in diagnosing nocturnal leg cramps: a systematic review. BMC Fam Pract. 2017; 18:1. 29
crossref

3. Grandner MA, Winkelman JW. Nocturnal leg cramps: Prevalence and associations with demographics, sleep disturbance symptoms, medical conditions, and cardiometabolic risk factors. PLoS One. 2017; 12:6. e0178465
crossref

4. Miller TM, Layzer RB. Muscle cramps. Muscle Nerve. 2005; 32:4. 431–42.
crossref

5. El-Tawil S, Al Musa T, Valli H, Lunn MP, Brassington R, El-Tawil T, et al. Quinine for muscle cramps. Cochrane Database Syst Rev. 2015; 4. CD005044


6. Katzberg HD, Khan AH, So YT. Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology. 2010; 74:8. 691–6.
crossref

7. Man-Son-Hing M, Wells G, Lau A. Quinine for nocturnal leg cramps: a meta-analysis including unpublished data. J Gen Intern Med. 1998; 13:9. 600–6.
crossref

8. Young G. Leg cramps. BMJ Clin Evid. 2015; 2015:pii:1113.


9. El-Tawil S, Al Musa T, Valli H, Lunn MP, El-Tawil T, Weber M. Quinine for muscle cramps. Cochrane Database Syst Rev. 2010; 12. CD005044


10. Man-Son-Hing M, Wells G. Meta-analysis of efficacy of quinine for treatment of nocturnal leg cramps in elderly people. BMJ. 1995; 310:6971. 13–7.
crossref

11. Young G. Leg cramps. BMJ Clin Evid. 2009; 2009:pii:1113.


12. Food and Drug Administration. FDA Drug Safety Communication: New risk management plan and patient Medication Guide for Qualaquin (quinine sulfate). 2010. Available at: https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm218202.htm


13. Blyton F, Chuter V, Walter KE, Burns J. Non-drug therapies for lower limb muscle cramps. Cochrane Database Syst Rev. 2012; 1:CD008496


14. Jones K, Castleden CM. A double-blind comparison of quinine sulphate and placebo in muscle cramps. Age Ageing. 1983; 12:2. 155–8.
crossref

15. Lim SH. Randomised double-blind trial of quinine sulphate for nocturnal leg cramp. Br J Clin Pract. 1986; 40:11. 462


16. Warburton A, Royston JP, O’Neill CJ, Nicholson PW, Jee RD, Denham MJ, et al. A quinine a day keeps the leg cramps away? Br J Clin Pharmacol. 1987; 23:4. 459–65.
crossref

17. Fung MC, Holbrook JH. Placebo-controlled trial of quinine therapy for nocturnal leg cramps. West J Med. 1989; 151:1. 42–4.


18. Connolly PS, Shirley EA, Wasson JH, Nierenberg DW. Treatment of nocturnal leg cramps. A crossover trial of quinine vs vitamin E. Arch Intern Med. 1992; 152:9. 1877–80.
crossref

19. Dunn NR. Effectiveness of quinine for night cramps. Br J Gen Pract. 1993; 43:368. 127–8.


20. Sidorov J. Quinine sulfate for leg cramps: does it work? J Am Geriatr Soc. 1993; 41:5. 498–500.
crossref

21. Diener HC, Dethlefsen U, Dethlefsen-Gruber S, Verbeek P. Effectiveness of quinine in treating muscle cramps: a double-blind, placebo-controlled, parallel-group, multicentre trial. Int J Clin Pract. 2002; 56:4. 243–6.


22. Woodfield R, Goodyear-Smith F, Arroll B. N-of-1 trials of quinine efficacy in skeletal muscle cramps of the leg. Br J Gen Pract. 2005; 55:512. 181–5.


23. Jansen PH, Veenhuizen KC, Verbeek AL, Straatman H. Efficacy of hydroquinine in preventing frequent ordinary muscle cramp outlasts actual administration. J Neurol Sci. 1994; 122:2. 157–61.
crossref

24. Jansen PH, Veenhuizen KC, Wesseling AI, de Boo T, Verbeek AL. Randomised controlled trial of hydroquinine in muscle cramps. Lancet. 1997; 349:9051. 528–32.
crossref

25. Baltodano N, Gallo BV, Weidler DJ. Verapamil vs quinine in recumbent nocturnal leg cramps in the elderly. Arch Intern Med. 1988; 148:9. 1969–70.
crossref

26. Young JB, Connolly MJ. Naftidrofuryl treatment for rest cramp. Postgrad Med J. 1993; 69:814. 624–6.
crossref

27. Prateepavanich P, Kupniratsaikul V, Charoensak T. The relationship between myofascial trigger points of gastrocnemius muscle and nocturnal calf cramps. J Med Assoc Thai. 1999; 82:5. 451–9.


28. Kim DH, Yoon DM, Yoon KB. The effects of myofascial trigger point injections on nocturnal calf cramps. J Am Board Fam Med. 2015; 28:1. 21–7.
crossref

29. Garrison SR, Allan GM, Sekhon RK, Musini VM, Khan KM. Magnesium for skeletal muscle cramps. Cochrane Database Syst Rev. 2012; 9. CD009402


30. Sebo P, Cerutti B, Haller DM. Effect of magnesium therapy on nocturnal leg cramps: a systematic review of randomized controlled trials with meta-analysis using simulations. Fam Pract. 2014; 31:1. 7–19.
crossref

31. Frusso R, Zárate M, Augustovski F, Rubinstein A. Magnesium for the treatment of nocturnal leg cramps: a crossover randomized trial. J Fam Pract. 1999; 48:11. 868–71.


32. Roffe C, Sills S, Crome P, Jones P. Randomised, cross-over, placebo controlled trial of magnesium citrate in the treatment of chronic persistent leg cramps. Med Sci Monit. 2002; 8:5. CR326–30.


33. Garrison SR, Birmingham CL, Koehler BE, McCollom RA, Khan KM. The effect of magnesium infusion on rest cramps: randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2011; 66:6. 661–6.
crossref

34. Molema MM, Dekker MC, Voermans NC, van Engelen BG, Aarnoutse RE. Caffeine and muscle cramps: a stimulating connection. Am J Med. 2007; 120:8. e1–2.
crossref

35. Coppin RJ, Wicke DM, Little PS. Managing nocturnal leg cramps--calf-stretching exercises and cessation of quinine treatment: a factorial randomised controlled trial. Br J Gen Pract. 2005; 55:512. 186–91.


36. Hallegraeff JM, van der Schans CP, de Ruiter R, de Greef MH. Stretching before sleep reduces the frequency and severity of nocturnal leg cramps in older adults: a randomised trial. J Physiother. 2012; 58:1. 17–22.
crossref

37. Choi SH, Shin YI, Lee JY. Case Study; Manual Therapy for Patients with Calf Cramps. Korean J Orthop Manu Ther. 2010; 16:2. 93–7.


38. Tahara E, Inutsuka H, Iwanaga J, Murai M, Ohtake M, Dokura J, et al. Four Patients with Calf Cramps who did not Respond to Shakuyakukanzoto but Responded well to Sokeikakketsuto. Kampo Med. 2011; 62:5. 660–3.
crossref

39. Ishida K. Efficacy of Goshajinkigan in the Treatment of Sleep-Related Leg Cramps : a Study of Distinctive Patient Features from the Viewpoint of Kampo Medicine. Kampo Med. 2014; 65:2. 100–7.
crossref

40. Ito T, Kimura Y, Ota S, Yamamoto S, Suda N, Nakazawa K. The Effectiveness of Shimotsuto Extract for Patients with Muscle Cramp. Kampo Med. 2015; 66:3. 244–9.
crossref

41. Kimura Y, Sato H, Ito T. Three Cases of Calf Cramps with Internal Coldness Caused by Kidney Deficiency Presenting with Gastrointestinal Dysfunction Successfully Treated with Shimbuto. Kampo Med. 2015; 66:4. 302–6.
crossref

42. Dokura J, Takahashi Y, Maeda H, Yoshinaga R, Inoue H, Yano H, et al. Review of 33 Patients in Whom Sokeikakketsuto was Used to Treat Recurrent Cramps of the Calf. Kampo Med. 2017; 68:1. 40–6.
crossref

43. Nakae H. Treatment of Painful Muscle Cramp Due to Heat Injury Using Shakuyakukanzoto. Kampo Med. 2013; 64:3. 177–83.
crossref

44. Wada K. Effect of Traditional Japanese Herbal (Kampo) Medicine, Goreisan, for Disdialysis and Muscle Cramps in Patients undergoing Maintenance Hemodialysis. Kampo Med. 2012; 63:3. 168–75.
crossref

45. Manjra SI. Muscle cramps in athletes [thesis]. St, Cape Town: University of Cape Town;1991.


46. Lee JH, Lim JY. Muscle Cramps in Old Adults: Clinical Features and Pathophysiology. J Korean Geriatr Soc. 2013; 17:4. 171–7.
crossref

Editorial office contact information
3F, #26-27 Gayang-dong, Gangseo-gu Seoul, 157-200 Seoul, Korea
The Society of Korean Medicine
Tel : +82-2-2658-3627   Fax : +82-2-2658-3631   E-mail : skom1953.journal@gmail.com
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Developed in M2PI